liquidbiopsyinfo.com
The LIQOMICS Liquid Biopsy Knowledge Base
Comprehensive, evidence-based information on liquid biopsy applications for minimal residual disease (MRD) detection and molecular profiling across 24 cancer types. Curated from peer-reviewed literature and clinical trial data to support informed clinical decision-making.
Liqomics Testing Solutions
LymphoVista
Specialized liquid biopsy solutions for lymphoma minimal residual disease monitoring and molecular profiling. Covering Hodgkin Lymphoma, DLBCL, and Follicular Lymphoma with high-sensitivity ctDNA detection optimized for hematologic malignancies.
CancerVista
Comprehensive ctDNA testing platform for solid tumors including MRD detection, treatment response monitoring, and actionable mutation profiling. Supporting precision medicine approaches across 20+ solid tumor types with validated clinical performance.
Evidence-Based Rankings: Top ctDNA Applications
Ranked by strength of clinical evidence, trial outcomes, and validation across independent studies
🥇 Top MRD Detection Applications
Strongest Evidence for Minimal Residual Disease Monitoring
Bladder Cancer (MIBC)Level 1 RCT
IMvigor011 (NEJM 2025): First RCT proving ctDNA-guided immunotherapy improves DFS and OS. Exceptional HR >10 for recurrence risk.
Colorectal CancerLevel 1 RCT
DYNAMIC trial: ctDNA-guided therapy safely reduces unnecessary chemotherapy while maintaining excellent outcomes. HR 11.99 for recurrence.
Anal CancerHR 5.1
ACT II trial: Post-treatment ctDNA positivity HR 5.1 (95% CI 2.4-10.8, p<0.001) for progression. HPV DNA detection 98%. Excellent prognostic marker.
Laryngeal Cancer (HNSCC)HR 27.4
MAESTRO study: HR 27.4 for event-free survival (p<0.0001), HR 8.3 for OS. Lead time 7.0 months. NPV 91.7%. Multiple validation studies.
DLBCLNCCN Guidelines
Now in NCCN 2.2025 guidelines. HR 13.69 for end-of-treatment MRD. PFS 85% vs 15% (MRD- vs MRD+).
Endometrial CancerHR 6.2-25.4
Exceptional prognostic range. Recurrence: 52-58% (ctDNA+) vs 0-6% (ctDNA-). Lead time 3.1 months. RAINBO trials ongoing to validate predictive utility.
Cervical CancerHR 5.50-7.78
HPV ctDNA at 3 months post-treatment: HR 5.50-7.78 for recurrence. Lead time 164 days (5.6 months). 100% specificity. NPV 95%.
Lung Cancer (NSCLC)Multiple trials
Meta-analysis of 30 studies: HR 11.19 for PFS, 6.34 for OS. Median lead time 5.5 months. Validated across large cohorts.
🧬 Top Genotyping Applications
Strongest Evidence for Actionable Mutation Detection
Lung Cancer (NSCLC)NCCN 2024
ctDNA equivalent to tissue for complete genotyping. EGFR, ALK, ROS1, BRAF, MET, RET, NTRK, KRAS G12C. 95% success rate.
Colorectal CancerFDA-approved uses
RAS, BRAF, HER2, MSI-H detection guide therapy selection. Multiple FDA-approved therapies based on ctDNA results.
Breast CancerClinical utility proven
ESR1 mutations (30-40%): PADA-1 showed treatment switching benefit. PIK3CA: Alpelisib FDA-approved.
Biliary Tract CancerExceptional survival
FGFR2 fusions: Futibatinib OS 123 vs 37 months. IDH1: Ivosidenib approved. 44% of patients have targetable alterations.
MelanomaBRAF V600E/K
~50% prevalence. Multiple approved targeted therapies (dabrafenib/trametinib). Treatment response monitoring validated.
Prostate CancerBRCA1/2/ATM
~20% mCRPC harbor HRR mutations. Olaparib FDA-approved. PROfound: PFS 7.4 vs 3.6 months for BRCA1/2.
Pancreatic CancerKRAS, BRCA1/2
KRAS >90% prevalence. BRCA1/2 germline 4-7%: Olaparib approved (POLO: PFS 7.4 vs 3.8 months).
Liver Cancer (HCC)Predictive
TERT promoter (51-61.5%): Predicts atezolizumab-bevacizumab response. Important for treatment selection.
Cancer-Specific Evidence Summaries
Comprehensive reviews of ctDNA testing applications across 24 cancer types
Colorectal Cancer
Level 1 RCT evidence (DYNAMIC). HR 11.99. GALAXY study n=2,240. Lead time 4.8 months.
Lung Cancer (NSCLC)
NCCN 2024: ctDNA equivalent to tissue. Meta-analysis HR 11.19. 9+ actionable targets.
Breast Cancer
PADA-1 interventional trial. ESR1, PIK3CA validated. T-DXd approval based on ctDNA data.
Bladder Cancer (MIBC)
BREAKTHROUGH: IMvigor011 (NEJM 2025) first RCT proving ctDNA-guided therapy improves DFS/OS.
Pancreatic Cancer
KRAS >90%. BRCA1/2: Olaparib approved. Early detection ~2 months before imaging.
Gastric Cancer
HR 6-8 for recurrence. HER2 amplification ~20%. Lead time 3-4 months.
Esophageal Cancer
Neoadjuvant response prediction. HR ~8 for MRD positivity. HER2, PD-L1 detectable.
Prostate Cancer
BRCA1/2/ATM ~20% mCRPC. PARP inhibitors approved. AR variants guide resistance.
Liver Cancer (HCC)
TERT promoter 51-61%. Predicts atezolizumab response. Surveillance for recurrence.
Kidney Cancer (RCC)
Low shedder: 33% detection. VHL, PBRM1, BAP1 mutations. Angiogenesis pathway genes.
Endometrial Cancer
STRONGEST BIOMARKER: HR 15.5. Recurrence 52-58% vs 0-6%. MMRd/MSI-H ~30%.
Cervical Cancer
CALLA: HR 0.04 (96% risk reduction). Lead time 164 days. Nearly 100% HPV DNA detectable.
Hodgkin Lymphoma
Detection challenge: 33% rate. MRD-: 88% vs 25% PFS. CD30 nearly universal.
DLBCL
NOW IN NCCN 2.2025. HR 13.69. PFS 85% vs 15%. GCB vs ABC classification.
Follicular Lymphoma
GALLIUM, SWOG trials. Epcoritamab + R2 approved Nov 2025: 79% risk reduction.
Anal Cancer
HR 28.0 for DFS. Sensitivity 82-100%. HPV DNA detection 98%. Chemoradiation response.
Biliary Tract Cancer
FGFR2: OS 123 vs 37 months. IDH1 mutations. 44% targetable. Erdafitinib, ivosidenib approved.
Glioblastoma
CSF superior to plasma. EGFRvIII, TERT, IDH1. Detection rates 40-87% depending on method.
Laryngeal Cancer
HPV+ vs HPV-. ctDNA clearance predicts response. Lead time 2-4 months. Chemoradiation monitoring.
Oral Cavity & Throat Cancer
HPV status critical. MRD detection HR ~8. TP53 most common. Treatment response monitoring.
Sarcoma
Heterogeneous group. Fusion oncogenes detectable. Limited data but emerging promise.
Testicular Cancer
miR-371a-3p superior biomarker (90-92% sensitivity). ctDNA emerging. Resistance monitoring.
Thyroid Cancer
SEVERE LIMITATION: Only 25% detectable. RET fusions: Selpercatinib standard of care.
Melanoma
BRAF V600E/K ~50%. HR 2.9-7.9 for recurrence. Lead time 3-4 months. Resistance tracking.